A new expert consensus on photodynamic therapy (PDT) for cervical squamous intraepithelial lesions (SIL) has been officially issued by the Chinese Society of Colposcopy and Cervical Pathology, the Chinese Society of Gynecologic Oncology, the Cervical Cancer Prevention and Control Committee of the China Maternal and Child Health Research Association, and the Cancer Prevention and Control Committee of the Chinese Preventive Medicine Association. The release of this consensus marks a significant step toward the standardized and evidence-based application of PDT in the management of cervical precancerous lesions in China.
The consensus draws on the latest domestic and international clinical evidence, offering a systematic review and recommendations for the use of PDT in SIL. This consensus follows the internationally recognized grading of recommendations, assessment, development, and evaluation (GRADE) methodology. It integrates expert consensus and the clinical practice in China, classifying the research evidence based on bias risk, inconsistency, indirectness, imprecision, and publication bias. The evidence levels are categorized as 1A, 1B, 2A, 2B, and 3. Notably, it affirms that Cevira® (Hexaminolevulinate Hydrochloride Ointment Photodynamic Therapy System) holds Level 1A evidence for the treatment of patients with cervical intraepithelial neoplasia grade 2 (CIN2). The highest tier of evidence—typically derived from rigorous meta-analyses or large-scale randomized controlled trials, with expert consensus exceeding 80%—underscores Cevira®’s proven efficacy and safety, and lays a solid academic foundation for its broader clinical adoption.
With the publication of this consensus, clinicians now have clear guidance to treatment strategies for cervical precancerous lesions. As a non-invasive, highly selective therapy, Cevira® enables effective disease management while preserving cervical integrity and reproductive potential. This makes it particularly suitable for younger women with fertility considerations, addressing key limitations associated with conventional surgical interventions that may compromise cervical function.
In the future, Asieris will continue to uphold a science-driven, clinically focused approach, generating high-quality evidence to support decision-making. The company is committed to expanding the use of non-invasive PDT in cervical disease management, offering patients safer and more effective treatment options, and contributing to the cervical cancer prevention and control in China.
About Asieris
Asieris Pharmaceuticals(688176.SH), founded in March 2010, is a global biopharma company specializing in discovering, developing and commercializing innovative drugs for the treatment of genitourinary tumors and women’s health. We strive to improve human health to preserve patient’s dignity. We aim to become a global pharma leader that integrates R&D, manufacturing and commercialization in our areas of focus.
Through proprietary R&D and strategic collaborations, the company is committed to developing first-in-class drugs and other innovative technologies and products that address significant unmet medical needs, building a robust portfolio spanning from disease diagnosis to treatment within its focused therapeutic areas. Driven by patient needs, we are comprehensively advancing Commercialization 2.0 to improve the accessibility and affordability of innovative products, thereby benefiting more patients in China and globally.
/* APL-1202 MIBC – ID selector override */ div#MIBC .elementor-progress-bar { width: 56% !important; }